Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
J Neurosci
2004 Mar 03;249:2322-7. doi: 10.1523/JNEUROSCI.4675-03.2004.
Show Gene links
Show Anatomy links
Propofol restores the function of "hyperekplexic" mutant glycine receptors in Xenopus oocytes and mice.
O'Shea SM
,
Becker L
,
Weiher H
,
Betz H
,
Laube B
.
???displayArticle.abstract???
Human hereditary hyperekplexia ("startle disease") is a neurological disorder characterized by exaggerated, convulsive movements in response to unexpected stimuli. Molecular genetic studies have shown that this disease is often caused by amino acid substitutions at arginine 271 to glutamine or leucine of the alpha1 subunit of the inhibitory glycine receptor (GlyR). When exogenously expressed in Xenopus oocytes, agonist responses of mutant alpha1(R271Q) and alpha1(R271L) GlyRs show higher EC50 values and lower maximal inducible responses (relative efficacies) compared with oocytes expressing wild-type alpha1 GlyR subunits. Here, we report that the maximal glycine-induced currents (I(max)) of mutant alpha1(R271Q) and alpha1(R271L) GlyRs were dramatically potentiated in the presence of the anesthetic propofol (PRO), whereas the I(max) of wild-type alpha(1) receptors was not affected. Quantitative analysis of the agonist responses of the isofunctionally substituted alpha1(R271K) mutant GlyR revealed that saturating concentrations of PRO decreased the EC50 values of both glycine and the partial agonist beta-alanine by >10-fold, with relative efficacies increasing by 4- and 16-fold, respectively. Transgenic (tg) mice carrying the alpha1(R271Q) mutation (tg271Q-300) have both spontaneous and induced tremor episodes that closely resemble the movements of startled hyperekplexic patients. After treatment with subanesthetic doses of PRO, the tg271Q-300 mutant mice showed temporary reflexive and locomotor improvements that made them indistinguishable from wild-type mice. Together, these results demonstrate that the functional and behavioral effects of hyperekplexia mutations can be effectively reversed by drugs that potentiate GlyR responses.
Andermann,
Startle disease or hyperekplexia: further delineation of the syndrome.
1980, Pubmed
Andermann,
Startle disease or hyperekplexia: further delineation of the syndrome.
1980,
Pubmed
Becker,
Transient neuromotor phenotype in transgenic spastic mice expressing low levels of glycine receptor beta-subunit: an animal model of startle disease.
2000,
Pubmed
Becker,
Disease-specific human glycine receptor alpha1 subunit causes hyperekplexia phenotype and impaired glycine- and GABA(A)-receptor transmission in transgenic mice.
2002,
Pubmed
Belelli,
The interaction of general anaesthetics and neurosteroids with GABA(A) and glycine receptors.
1999,
Pubmed
,
Xenbase
Clements,
Transmitter timecourse in the synaptic cleft: its role in central synaptic function.
1996,
Pubmed
Colquhoun,
Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutating receptors.
1998,
Pubmed
Floeter,
Glycine receptors: a startling connection.
1993,
Pubmed
Hadipour-Jahromy,
Binary combinations of propofol and barbiturates on human alpha(1) glycine receptors expressed in Xenopus oocytes.
2003,
Pubmed
,
Xenbase
Irifune,
Propofol-induced anesthesia in mice is mediated by gamma-aminobutyric acid-A and excitatory amino acid receptors.
2003,
Pubmed
Jurd,
General anesthetic actions in vivo strongly attenuated by a point mutation in the GABA(A) receptor beta3 subunit.
2003,
Pubmed
Langosch,
Decreased agonist affinity and chloride conductance of mutant glycine receptors associated with human hereditary hyperekplexia.
1994,
Pubmed
,
Xenbase
Laube,
Potentiation of inhibitory glycinergic neurotransmission by Zn2+: a synergistic interplay between presynaptic P2X2 and postsynaptic glycine receptors.
2002,
Pubmed
Laube,
Modulation of glycine receptor function: a novel approach for therapeutic intervention at inhibitory synapses?
2002,
Pubmed
Laube,
Hyperekplexia mutations of the glycine receptor unmask the inhibitory subsite for beta-amino-acids.
1995,
Pubmed
,
Xenbase
O'Shea,
Propofol increases agonist efficacy at the GABA(A) receptor.
2000,
Pubmed
Schofield,
The role of glycine and glycine receptors in myoclonus and startle syndromes.
2002,
Pubmed
Shiang,
Mutations in the alpha 1 subunit of the inhibitory glycine receptor cause the dominant neurologic disorder, hyperekplexia.
1993,
Pubmed
Stayer,
Stiff-man syndrome: an overview.
1998,
Pubmed
Stewart,
Successful treatment of severe infantile hyperekplexia with low-dose clobazam.
2002,
Pubmed
Zhou,
Hyperekplexia: a treatable neurogenetic disease.
2002,
Pubmed
